Clinical trials are an essential tool in modern medicine. Clinical trials are research investigations in which people voluntarily participate in studies for new treatments and interventions to prevent, diagnose or manage blood disorders. They are crucial for the development of new medical treatments and help determine if new medicines are effective, safe and/or better than the current treatments available.Clinical trials aim to answer the following questions in a controlled environment:
Clinical trials are the final step in a long process that begins with research in a laboratory. Our current active clinical trials are outlined below.
Please visit Participate in a clinical trial for details on how to participate in a trial, or contact us for further information.
Summaries of PBI's previous clinical trials can be found in our archived projects.
An observational study of patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network. Read more
A study of Bendamustine and Rituximab alone versus in combination with Acalabrutinib in subjects with previously untreated Mantle Cell Lymphoma. Read more
To study the safety and efficacy of Copanlisib in combination with Rituximab in patients with relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL). Read more
To evaluate the efficacy and safety of MOR208 with Bendamustine versus Rituximab with Bendamustine in adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL). Read more
Study the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and combined with Atezolizumab in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Read more
Study of the safety, pharmacokinetics, and clinical activity of PRN1008, an oral BTK inhibitor, in patients with relapsed Immune Thrombocytopenic Purpura. Read more
Study of ME-401 in subjects with Follicular Lymphoma after failure of two or more prior systemic therapies. Read more
To compare the efficacy and safety of Luspatercept (ACE-536) versus Epoetin Alfa for the treatment of anaemia due to I PSS-R, very low, low or intermediate risk Myelodysplastic syndromes in ESA Naïve subjects who require red blood cell transfusions. Read more
Study of Venetoclax and Dexamethasone compared with Pomalidomide and Dexamethasone in subjects with t(11;14)-positive relapsed or refractory Multiple Myeloma. Read more
To assess the efficacy and safety of BIVV009 in patients with primary cold agglutinin disease without a recent history of blood transfusion. Read more
A study to evaluate the efficacy, safety, and pharmacokinetics of Prophylactic Emicizumab versus No Prophylaxis in Hemophilia participants without inhibitors. Read more
A study comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in subjects with previously untreated Multiple Myeloma who are ineligible for High Dose Therapy. Read more
A study evaluating Venetoclax (ABT-199) in Multiple Myeloma subjects who are recieving Bortezomib and Dexamethasone. Read more
To study Oprozomib in combination with Pomalidomide and Dexamethasone in relapsed or refractory Multiple Myeloma. Read more
A study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant Eligible For Transplant. Read more
A study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis®) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines. Read more
A study of subcutaneous Daratumumab versus active monitoring in subjects with high-risk smouldering multiple myeloma. Read more
A study of GDC-0199 (ABT-199) plus Rituximab compared with Bendamustine plus Rituximab in patients with relapsed or refractory chronic Lymphocytic Leukemia. Read more
A study evaluating Venetoclax in subjects with Chronic Lymphocytic Leukemia whose cancer has come back or had no response to previous cancer treatments. Read more
Study of Acalabrutinib (ACP-196) versus investigator's choice of either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia. Read more
A study of the current practice in major centres in Australia and New Zealand for achieving haemostasis in consecutive patients who present with significant haemorrhage, thromboembolism or urgent surgery whilst on new or established oral anticoagulants. Read more